Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Catalent, Inc. Common Stock (NY:CTLT)

63.48 UNCHANGED
Last Price Updated: 7:00 PM EST, Dec 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Catalent, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Target Reports Earnings Beat, Joins AST SpaceMobile, Dada Nexus And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones gaining more than 100 points on Wednesday. Shares of Target Corporation (NYSE: TGT) jumped during Wednesday’s session after the company reported... 
Via Benzinga
Topics Earnings Stocks
US Stocks On Track To Build On Gains As Traders Await A Batch Of Data; Can Market Resist Profit Taking?
U.S. stocks could build on the momentum they picked up on Tuesday following the release of benign inflation data. Traders get to digest another batch of economic data on producer price inflation,... 
Via Benzinga
Topics Economy
Recap: Catalent Q1 Earnings
Via Benzinga
Preview: Catalent's Earnings
Via Benzinga
Analyst Ratings for Catalent
Via Benzinga
15 Analysts Have This to Say About Catalent
Via Benzinga
Catalent Earnings Preview
Via Benzinga
BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake
The company's recently FDA-approved gene therapy is struggling to gain traction. 
Via Investor's Business Daily
What's Going On With Biotech Contract Service Firm Catalent Stock Today?
Catalent Inc (NYSE: CTLT) shares are trading lower due to its significant exposure to Sarepta Therapeutics Inc (NASDAQ: SRPT) on the back of disappointing data from a pivotal gene therapy trial. 
Via Benzinga
Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for... 
Via Benzinga
Topics Intellectual Property
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another busy day of trading as we go over the biggest pre-market stock movers worth watching on Tuesday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Weight-Loss Drug Boom Has Another Ripple Effect - Rapid Growth Expected In Fill-Finish Market
Contract drug manufacturers are investing billions of dollars in expanding or constructing facilities that fill the injection pens used for weight-loss drugs like Novo Nordisk A/S's (NYSE: NVO)... 
Via Benzinga
3 Debt-Ridden S&P 500 Stocks to Sell Before It’s Too Late
With debt getting more expensive, it’s become easier to recommend unloading these three S&P 500 stocks now. 
Via InvestorPlace
Topics Stocks
Benzinga's Top Ratings Upgrades, Downgrades For September 5, 2023
Via Benzinga
Barron's Weekend Stock Picks: Globalstar Satellites, Catalent And Dell's Delightful Destiny
Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read. 
Via Benzinga
Why Catalent Stock Zoomed 12% Higher This Week
A strong earnings report and a clutch of analyst price target hikes will do that. 
Via The Motley Fool
Catalent's Activist Board Presence To Boost Operational Recovery, Analyst Says
Tuesday, Catalent Inc (NYSE: CTLT) reported Q4 adjusted EPS of $0.09, missing the consensus of $0.10, with sales of $1.07 billion, down 17% Y/Y, slightly above the  
Via Benzinga
RBC Capital Maintains Outperform Rating for Catalent: Here's What You Need To Know
Via Benzinga
Why Catalent Stock Surged Nearly 5% Higher Today
Fourth-quarter performance that wasn't too disappointing, plus a settlement with an activist investor, brought some bulls back to the company's shares. 
Via The Motley Fool
Workhorse Fails to Get Enough Votes to Increase WKHS Stock Count
Workhorse (WKHS) stock is on the move Tuesday after the company failed to get shareholder approval to increase its share count. 
Via InvestorPlace
Can a New CFO Save Canoo (GOEV) Stock?
Canoo (GOEV) stock is getting a boost on Tuesday as investors react to the company naming its new Chief Financial Officer. 
Via InvestorPlace
ORCL Stock Alert: Can AI Hype Really Boost Oracle 20%?
Oracle (ORCL) stock is in the news Tuesday as UBS analyst Karl Keirstead makes a bull case for the information technology company's shares. 
Via InvestorPlace
Topics Artificial Intelligence
China's Response To Shield Economy From Real Estate Storm, Biden Targets Cancer, Diabetes Drugs In Controversial Medicare Price Battle, Google Collaborates With Nvidia In AI Expansion: Today's Top Stories
Bloomberg China Takes Drastic Measures To Shield Economy From Real Estate Storm 
Via Benzinga
Topics Artificial Intelligence Economy
Catalent (CTLT) Stock Gains on Elliott Deal
Catalent (CTLT) stock is getting a boost on Tuesday after the company reached an agreement with Elliott Investment Management. 
Via InvestorPlace
Beaten Down COVID-19 Vaccine Partner Stock Catalent Finalizes Deal With Activist Investor, Reports Mixed Q4 Earnings
Catalent Inc (NYSE: CTLT), valued at around $8 billion, has finalized a deal with activist investor Elliott Investment Management.  
Via Benzinga
Wegovy's Massive Demand: Novo Nordisk CEO Expresses Full Confidence In Catalent Amid Manufacturing Hurdles
Novo Nordisk A/S's (NYSE: NVO) CEO, Lars Fruergaard Jorgensen, expressed confidence in Catalent Inc's (NYSE: CTLT) capability to rectify its manufacturing issues related to its  
Via Benzinga
Why Novo Nordisk Stock Was Racing Higher on Wednesday
When you have a hot item on the market, it's wise to ramp up production. 
Via The Motley Fool
One Is Not Enough For Famed Weight Loss Drug: Novo Nordisk Taps Thermo Fisher To Ramp Up Wegovy Production
Novo Nordisk A/S (NYSE: NVO) has reportedly enlisted the services of Thermo Fisher Scientific Inc (NYSE: TMO) as its second contract manufacturer for its highly sought-after  
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.